Interax Biotech Ltd. and Alveus Therapeutics Inc. have signed a strategic research collaboration and licensing agreement to develop a differentiated small-molecule candidate for metabolic disease. Designed to overcome the limitations of current obesity medications, the candidate is expected to deliver durable weight loss with superior tolerability.